Partial load-bearing rabbit ulnar segmental defects are regenerated with biocompatible grafts with or without bone marrow-derived mesenchymal stem cells
Basaran SH., Bayrak A., Tanrıverdi G., Tanriverdi B., Avkan MC.
Animal Study, published in Ulus Travma Acil Cerrahi Derg (2022) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Ulus Travma Acil Cerrahi Derg (2022)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 35920424
- PMCID
- PMC10315982
- DOI
- 10.14744/tjtes.2021.64569
Abstract (original English)
Background The autologous bone grafts still have been used as the gold standard to initiate and facilitate bone healing in cases with bone defects. Because of some disadvantages of autologous bone grafts, the new biocomposite grafts have been researched. The purpose of the present study was to investigate whether the bone marrow-derived mesenchymal stem cells (BM-MSCs) loaded into a biocomposite scaffold enhance bone regeneration. Methods In our study, a 10 mm osteoperiosteal segmental bone defect was created in the middle of the right and left ulnar bones of eight rabbits. The created defects were filled in the right ulnar bones of eight rabbits (Group I) with BM-MSCs loaded onto a bio-composite scaffold (Plexur PTM, Osteotech, Eatontown, NJ, USA) and in the other ulnar bones of the same rabbits (Group II) with only biocomposite graft. Radiographs of each forelimb were taken postoperatively at the end of the 6th week. Then, the rabbits were euthanized pharmacologically for histopathological evaluation. Results Were scored using a modified Lane and Sandhu scoring system. All defects healed in both groups. Radiological and histo-logical total scores were slightly better in Group I, but statistical tests did not reveal any significant differences between the two groups at the end of the 6th week radiologically and histologically (p>0.05). Conclusion The results of our study demon
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.